Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Luye In-Licenses China Rights to Cancer Drug from Korea's Hanmi Pharm

publication date: Aug 22, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Luye Pharma of Yantai, China in-licensed a novel oncology drug candidate from Korea's Hanmi Pharmaceutical. Under the terms of the agreement, Luye will have China rights to develop and sell poziotinib, a pan-HER inhibitor. Hanmi will receive an upfront payment plus development and regulatory milestones that total up to $20 million. According to Hanmi, poziotinib has a novel, oral mechanism that blocks EGFR receptors and may be effective against various forms of cancer. More details....

Stock Symbols: (HK: 2186) (KRX: 128940)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...